CliffBio
biologic

Bioclate (Armour), Recombinate

Antihemophilic Factor (Recombinant)

Loss of exclusivityDecember 2004projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameBioclate (Armour), Recombinate
Active ingredientAntihemophilic Factor (Recombinant)
Strength500IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 1992
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Bioclate (Armour), Recombinate patent cliff — loss of exclusivity December 2004 | CliffBio